On March 31, 2021 BioCanRx researchers Dean Fergusson, Justin Presseau, Natasha Kekre, Harold Atkins, Kednapa Thavorn, Rob Holt, Manoj Lalu, and patient representative Terry Hawrysh reported that they have recently published results in two medical journals from their BioCanRx-funded project, "Getting better Outcomes with Chimeric Antigen Receptor T-cell therapy (GO–CART): A BioCanRx Research Excelerator to Safely and Effectively Translate CAR T-Cell Therapy for Hematological Malignancies" (Press release, BioCanRx, MAR 31, 2021, View Source;utm_medium=rss&utm_campaign=biocanrx-funded-researchers-publish-results-car-t-csei-project [SID1234577433]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study, which began in 2017, aimed to bring together experts from different backgrounds as well as patient representatives to formulate a feasible, safe, effective, and economical trial protocol that addressed the pitfalls some early-phase trials have faced in the past. Its ultimate aim was to help BioCanRx scientists effectively use CAR T cells in Canada.
Read about the results of their research below:
Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial
Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials